Primary Ciliary Dyskinesia Market: By Diagnosis (Genetic Testing, Electron Microscopy, and other), By Treatment (Radiotherapy, Chemotherapy, others), and By End User (Hospitals & Clinics, Research Centers, and others) - Global Forecast till 2023

Market Scenario

Primary ciliary dyskinesia (PCD), also known as immotile ciliary syndrome or Kartagener syndrome. Primary ciliary dyskinesia is a rare disorder and is a type of chronic respiratory tract infections, normally occurs in internal organs of human body. The major symptoms of this condition are caused by abnormal cilia and flagella. Normally cilia are microscopic, finger-like projections that stick out from the surface of cells. They are found in the linings of the airway, the reproductive system, and other organs and tissues. Flagella are tail-like structures, similar to cilia that propel sperm cells forward.

In some cases, mutations in the genes can cause primary ciliary dyskinesia result in defective cilia that move abnormally or are unable to move. As cilia have many important functions within the body, defects in these cell structures cause diseased condition.

Increasing prevalence of respiratory tract diseases is one of the major factors for the growth of the market during the forecast period. According to the Centers for Disease Control and Prevention (2014), 9.3 million adults diagnosed with respiratory problems. Whereas, 147,101 deaths occurred due to chronic lower respiratory diseases. It is predicted to be the 3rd most death causing factor.

According to the World Health Organization (WHO), over 7 million deaths occur each year of which more than 6 million deaths result from direct use of tobacco. Moreover, according to Eurostat's, (2014), COPD (Chronic Obstructive Pulmonary Disease) affected more than 200 million people worldwide and is one of the major diseases whose prevalence is increasing across the globe.

However, high cost of the current treatment methods and lack of awareness about rare respiratory diseases such as primary ciliary dyskinesia may hamper the market growth over the review period.

The global primary ciliary dyskinesia market is expected to grow at a CAGR of ~6.7% during the forecast period 2017-2023.

Key Players


Intended Audience
Market Segmentation

The global primary ciliary dyskinesia market is segmented on the basis of diagnosis, treatment, and end user.

On the basis of diagnosis, the market is segmented into genetic testing, electron microscopy, and others.

On the basis of treatment, the market is categorized into drug treatment, radiotherapy, chemotherapy, others. On the basis of drug treatment, it is further segmented into clarithromycin, erythromycin and azithromycin, and others.

On the basis of end user, the market is segmented into hospitals & clinics, research centers, and others.

**Figure: Global PCD Market, by Treatment, 2016 (%)**

Source: World Health Organization, Centers for Disease Control and Prevention, expert interview market research future analysis, annual report, white paper, company presentation

Regional Analysis

The Americas dominates the global primary ciliary dyskinesia market owing to the presence of strong economic condition, huge development in healthcare domain, and focus of research institutions on updating technology for rare diseases diagnosis and treatment methods. Moreover, advanced hospitals infrastructures, availability of skilled healthcare professional are boosting the growth of the market.

Europe holds the second largest primary ciliary dyskinesia market across the globe due to encouraging government policies for research & development and healthcare professionals by various European countries such as France and Germany. Moreover, according to Eurostat’s, (2014), over 401000 deaths were caused by respiratory system diseases, which are equivalent to 8.0 % of all deaths. Proportion of deaths in the UK from respiratory diseases is considerably higher than the other European countries, which will drive the market growth in this region during the forecast period.

Asia Pacific is the fastest growing market owing to more number of developing nations present in this region, for instance, countries like India, China are encouraging the
growth of the healthcare domain. Furthermore, increasing patient population from respiratory diseases in developing countries will directly increase the demand for various treatment methods and will boost the growth of the market.

The Middle East & Africa is expected to hold the least market share due to less availability of medical facilities, and less development in the healthcare domain. However, countries such as Qatar and Kuwait are focusing more in healthcare domain and developing medical facilities, which will boost the market growth in this region.

Research Methodology

Source: World Health Organization, Centers for Disease Control and Prevention, expert interview market research future analysis, annual report, white paper, company presentation

Contents:

<table>
<thead>
<tr>
<th>Contents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table of Content</td>
</tr>
<tr>
<td>1. Report Prologue</td>
</tr>
<tr>
<td>2. Market Introduction</td>
</tr>
<tr>
<td>2.1 Definition</td>
</tr>
<tr>
<td>2.2 Scope of the Study</td>
</tr>
<tr>
<td>2.2.1 Research Objective</td>
</tr>
<tr>
<td>2.2.2 Assumptions</td>
</tr>
<tr>
<td>2.2.3 Limitations</td>
</tr>
<tr>
<td>3. Research Methodology</td>
</tr>
<tr>
<td>3.1 Introduction</td>
</tr>
<tr>
<td>3.2 Primary Research</td>
</tr>
<tr>
<td>3.3 Secondary research</td>
</tr>
<tr>
<td>3.4 Market Size Estimation</td>
</tr>
<tr>
<td>4. Market Dynamics</td>
</tr>
<tr>
<td>4.1 Drivers</td>
</tr>
<tr>
<td>4.2 Restrains</td>
</tr>
<tr>
<td>4.3 Opportunities</td>
</tr>
<tr>
<td>4.4 Challenges</td>
</tr>
<tr>
<td>4.5 Macroeconomic Indicators</td>
</tr>
<tr>
<td>4.6 Technology Trends &amp; Assessment</td>
</tr>
<tr>
<td>5. Market Factor Analysis</td>
</tr>
<tr>
<td>5.1 Porters Five Forces Analysis</td>
</tr>
<tr>
<td>5.1.1 Bargaining Power of Suppliers</td>
</tr>
</tbody>
</table>
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
6. Global Primary Ciliary Dyskinesia Market, by Diagnosis
  6.1 Introduction
  6.2 Genetic Testing
    6.2.1 Market Estimates & Forecast, 2017-2023
  6.3 Electron Microscopy
    6.3.1 Market Estimates & Forecast, 2017-2023
7. Global Primary Ciliary Dyskinesia Market, by Treatment
  7.1 Introduction
  7.2 Drug Treatment
    7.2.1 Market Estimates & Forecast, 2017-2023
  7.3 Radiotherapy
    7.3.1 Market Estimates & Forecast, 2017-2023
  7.4 Chemotherapy
    8.4.1 Market Estimates & Forecast, 2017-2023
8. Global Primary Ciliary Dyskinesia Market, by End User
  8.1 Introduction
  8.2 Hospitals & Clinics
    8.2.1 Market Estimates & Forecast, 2017-2023
  8.3 Research Centers
    8.3.1 Market Estimates & Forecast, 2017-2023
9. Global Primary Ciliary Dyskinesia Market, by Region
  9.1 Introduction
  9.2 Americas
    9.2.1 North America
      9.2.1.1 US
      9.2.1.1 Canada
    9.2.2 South America
  9.3 Europe
    9.3.1 Western Europe
      9.3.1.1 Germany
      9.3.1.2 France
      9.3.1.3 UK
      9.3.1.4 Italy
      9.3.1.5 Spain
      9.3.1.6 Rest of Western Europe
    9.3.2 Eastern Europe
  9.4 Asia Pacific
    9.4.1 Japan
    9.4.2 China
    9.4.3 India
    9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of the Middle East & Africa

10 Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments

11 Company Profiles
11.1 AstraZeneca
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financials
11.1.4 SWOT Analysis
11.2 Boehringer Ingelheim GmbH
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 Novartis AG
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Teva UK Limited
11.4.1 Company Overview
11.4.2 Product/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 Bayer AG
11.5.1 Company Overview
11.5.2 Product Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.6 Rotech Healthcare Inc.
11.6.1 Company Overview
11.6.2 Product Overview
11.6.3 Financial Overview
11.6.4 Key Developments
LIST OF FIGURES

Figure 1 Research Process
Figure 2 Segmentation for Global Primary Ciliary Dyskinesia Market
Figure 3 Segmentation Market Dynamics for Primary Ciliary Dyskinesia Market
Figure 4 Global Primary Ciliary Dyskinesia Market Share, by Diagnosis 2016
Figure 5 Global Primary Ciliary Dyskinesia Market Share, by Treatment 2016
Figure 6 Global Primary Ciliary Dyskinesia Market Share, by End Users, 2016
Figure 7 Global Primary Ciliary Dyskinesia Market Share, by Region, 2016
Figure 8 North America Primary Ciliary Dyskinesia Market Share, by Country, 2016
Figure 9 Europe Primary Ciliary Dyskinesia Market Share, by Country, 2016
Figure 10 Asia Pacific Primary Ciliary Dyskinesia Market Share, by Country, 2016
Figure 11 Middle East & Africa Primary Ciliary Dyskinesia Market Share, by Country, 2016
Figure 12 Global Primary Ciliary Dyskinesia Market: Company Share Analysis, 2016 (%)
Figure 13 Rotech Healthcare Inc.: Key Financials
Figure 14 Rotech Healthcare Inc.: Segmental Revenue
Figure 16 Rotech Healthcare Inc.: Geographical Revenue
Figure 17 Bayer AG: Key Financials
Figure 18 Bayer AG: Segmental Revenue
Figure 19 Bayer AG: Geographical Revenue
Figure 20 Novartis AG: Key Financials
Figure 21 Novartis AG: Segmental Revenue
Figure 22 Novartis AG: Geographical Revenue
Figure 23 Teva UK Limited: Key Financials
Figure 24 Teva UK Limited: Segmental Revenue
Figure 25 Teva UK Limited: Geographical Revenue
Figure 26 AstraZeneca: Key Financials
Figure 27 AstraZeneca: Segmental Revenue
Figure 28 AstraZeneca: Geographical Revenue
Figure 29 Boehringer Ingelheim GmbH: Key Financials
Figure 30 Boehringer Ingelheim GmbH: Segmental Revenue
Figure 31 Boehringer Ingelheim GmbH: Geographical Revenue
Figure 32 Pfizer Inc: Key Financials
Figure 33 Pfizer Inc: Segmental Revenue
Figure 34 Pfizer Inc: Geographical Revenue